Outsource your regulatory, clinical & commercial qualification services to US Experts
US Go-To Market Consulting firm
◦ Accelerate Your US Market Entry
◦ Bring Your Disruptive Medical Device, Drug Treatments in front of US Commercial Partners
Who are Scan MedPartners, LLC
Accelerate Your US Market Entry
Committed To Our Clients Retaining 1st Mover Market Advantage
Committed To Our Clients Retaining 1st Mover Market Advantage
• Scan MedPartners (SMP) is very different from general market entry consultants that only offer limited US market information and guidance, only keen to support getting standard distribution agreements signed.
• These consultants don't allocate time to navigate the complex pipeline decision process, and don’t provide support during the
• Scan MedPartners (SMP) is very different from general market entry consultants that only offer limited US market information and guidance, only keen to support getting standard distribution agreements signed.
• These consultants don't allocate time to navigate the complex pipeline decision process, and don’t provide support during the critical phases of commercial execution, pre- and post-launch.
• Scan MedPartners remain involved throughout the commercial launch phase and following years, to maximize sales performance and ensure there is no reduction in focus after the distribution/co-development/licensing contract is negotiated.
Committed To Our Clients Retaining 1st Mover Market Advantage
Committed To Our Clients Retaining 1st Mover Market Advantage
Committed To Our Clients Retaining 1st Mover Market Advantage
• Scan MedPartners Provide Regulatory Strategy, Minimal Clinical Services To Reduce Cost, and Shorten FDA Clearance.
• Established CRO’s (Clinical Research Organizations) are directly compensated, the longer, the more complex label claims they plan for. These firms are not incentivized to recommend shortest regulatory approval pathway!
•
• Scan MedPartners Provide Regulatory Strategy, Minimal Clinical Services To Reduce Cost, and Shorten FDA Clearance.
• Established CRO’s (Clinical Research Organizations) are directly compensated, the longer, the more complex label claims they plan for. These firms are not incentivized to recommend shortest regulatory approval pathway!
• We are committed, developing your reimbursement strategy, and to developing a cost and time sensitive regulatory proposal.
• We’re specialized developing the fastest go-to market regulatory strategy, not just planning for the high risk regulatory clearance / approval claims, rather speed to filing to get to your first 'clearance level' matters more that a high-risk, resource, time intensive higher level regulatory clearance.
• Seek a second option, and let us manage your FDA Pre-submission meetings, for the purpose of validating, recommended the first mover market advantage regulatory pathways.
Results Oriented
Committed To Our Clients Retaining 1st Mover Market Advantage
Results Oriented
• Scan MedPartners are connecting US and Scandinavian Scale-ups and Start-ups with the right US Key Portfolio Decision Makers. Top level US executive with direct responsibility adding new incremental revenue to further fuel the sales growth of these US Partner Companies.
• Scan MedPartners have multi-year deep industry network across the U
• Scan MedPartners are connecting US and Scandinavian Scale-ups and Start-ups with the right US Key Portfolio Decision Makers. Top level US executive with direct responsibility adding new incremental revenue to further fuel the sales growth of these US Partner Companies.
• Scan MedPartners have multi-year deep industry network across the US, and we are experts finding and qualifying the right New Innovation, Portfolio owners and translating the value of our transformative client's innovations across many specialized therapeutic areas.
• With a strong customer orientation and extensive direct relationships with Medical Industry Executives, Medical Thought Leaders, as well as hospital administrators; Scan MedPartners are committed to supporting our clients new innovated, disruptive and transformative treatments, to improve outcomes for patients, providers, and lower the total costs of care across the USA.